logo
Plus   Neg
Share
Email

Novavax: Influenza Vaccine NanoFlu Meets Primary Goals In Phase 3 Clinical Trial

Novavax Inc. (NVAX), a late-stage biotechnology company developing vaccines for serious infectious diseases, announced Tuesday positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu. In pre-market activity on Nasdaq, Novavax shares were gaining around 37.08 percent at $14.75.

In a statement, the company said that NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with its proprietary Matrix-M adjuvant, achieved all primary endpoints in Phase 3 clinical trial in adults aged 65 and older.

The trial used the Food and Drug Administration's criteria for accelerated approval of seasonal influenza vaccines. It evaluated the immunogenicity and safety of NanoFlu compared to Fluzone Quadrivalent, a U.S.-licensed quadrivalent influenza vaccine.

The trial also achieved statistical significance in key secondary endpoints.

Novavax said it will submit a U.S. BLA under FDA's accelerated approval pathway.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Latam Airlines Group SA, one of the largest air carrier in South America, has filed for bankruptcy protection in New York amid the ongoing Covid-19 pandemic, which has grounded flights worldwide. This Chapter 11 filing allows Latam to work with its creditors and other stakeholders to reduce its debt,... Pizza Hut said it is giving away 500,000 free pizzas to 2020 graduates in the Unites States. The pizza chain, owned by Yum! Brands, offers one free medium 1-topping pizza to all diploma/degree earning individuals until supplies last. The company is partnering with America's dairy farmers for the offer, which can be claimed until Thursday and redeemed until June 4. Merck & Co. Inc. on Tuesday announced deals, including an acquisition and two collaborations that will enable the U.S. drugmaker to join the race to develop coronavirus vaccines and drugs. Shares of Merck were rising almost 4 percent in the pre-market. Merck said it has agreed to acquire privately-held Themis, an Austria-based company focused on vaccines and immune-modulation therapies.
Follow RTT